Inflammatory Bowel Disease (IBD) is a term used to describe two chronic inflammatory diseases of the gastrointestinal tract: Crohn’s disease and ulcerative colitis. Both conditions cause inflammation in the intestines and have no cure, affecting an estimated 7–10 million people worldwide. The prevalence of IBD is increasing, and while there are treatments available to reduce flare-ups, inflammation, and symptoms, most patients require lifelong management with various therapeutic approaches. The disease is highly complex and associated with many long-term complications, which can be further exacerbated by the side effects of medications commonly prescribed to manage symptoms.

MedBiome has developed an innovative approach using its RapidAIM platform to improve upon the standard of care. This method combines a personalized diagnostic test with a tailored nutritional supplement designed to match the patient’s unique microbiome. The diagnostic test assesses the patient’s microbiome composition, enabling the selection of a specific nutritional supplement that enhances beneficial and anti-inflammatory functions of their microbiome. 

MedBiome is preparing to introduce this product to market under the brand NutraTune. Please contact us for more details at info@medbiome.ca.